DIVISLAB Share Price Performance
₹0
-6031.50 (-100.00%)
Price ₹0
Fair Value₹8,447.00
Share Pricen/a
Narrative Update • Sep 03
Divi's Laboratories Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
DIVISLAB Community Narratives
AN
Fair Value
·Fair Value ₹8.45k 12.3% overvalued intrinsic discount
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
1users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
AN
Fair Value
·Fair Value ₹6k 58.1% overvalued intrinsic discount
Rising Protectionism And Regulatory Burdens Will Undermine Pharma Exports
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹10.95k 13.4% undervalued intrinsic discount
Custom Synthesis And Green Chemistry Will Harness Rising Pharmaceutical Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Divi's Laboratories
12.3% overvalued intrinsic discount
Updated
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
View narrativeAN
Updated 3 Sep
Divi's Laboratories
13.4% undervalued intrinsic discount
Custom Synthesis And Green Chemistry Will Harness Rising Pharmaceutical Demand
View narrativeAN
Updated 20 Aug
Divi's Laboratories
58.1% overvalued intrinsic discount
Rising Protectionism And Regulatory Burdens Will Undermine Pharma Exports
View narrativeAN
Updated 6 Aug
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
DIVISLAB: Board Review Of June Quarter Results Will Shape Balanced Outlook
Fair Value: ₹8.45k 12.3% overvalued intrinsic discount
14 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Fair Value: ₹10.95k 13.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Fair Value: ₹6k 58.1% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Flawless balance sheet with proven track record and pays a dividend.
1 Risk
2 Rewards
Divi's Laboratories Limited Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- 110.18
- 61.24%
- 26.05%
- 0.04%
About DIVISLAB
- Founded
- 1990
- Employees
- 11565
- CEO
- WebsiteView website
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Recent DIVISLAB News & Updates
Narrative Update • Aug 20
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.
Narrative Update • Aug 06